Genomics and synthetic biology are reshaping healthcare, as rapid DNA sequencing advances power personalized medicine and strong market growth.

MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on Monday, March 2, 2026, at 2:30 PM ET in Boston, MA.

Pacific Biosciences of California, Inc. (PACB) Q4 2025 Earnings Call Transcript

PACB beats Q4 estimates as revenue jumps 14%, gross margin hits 41% and 2026 revenues are projected in the range of $165-$180M after strategic moves.

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.2 per share a year ago.

MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of select intellectual property and other assets related to PacBio's short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina, Inc.

Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) has been given an average recommendation of "Hold" by the seven brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have given a buy recommendation

In the most recent trading session, Pacific Biosciences of California (PACB) closed at $2.26, indicating a -4.64% shift from the previous trading day.

Pacific Biosciences is transitioning to a recurring revenue model as consumables reach a record 55% of Q3 revenue, driving margin improvements. Non-GAAP gross margin hit 42% in Q3, with management attributing gains to a favorable mix shift and yield improvements, notably from multi-use SMRT Cells. Cash burn is materially lower, with year-end cash at $279.5M and Q3 burn around $16M, supporting the company's path toward self-funding.

MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, at 5:00 pm Eastern Time.